Updated:
Centauri Therapeutics Limited
Centauri Therapeutics is an immunotherapy company developing Alphamer® technology for infectious diseases and oncology, backed by CARB-X and AMR Action...
Centauri Therapeutics Limited
Centauri Therapeutics is an immunotherapy company focused on infectious diseases and oncology, built around a proprietary Alphamer® technology platform. The firm’s approach harnesses a clinically validated immune mechanism that redirects naturally existing antibodies to treat life-threatening diseases. Its leadership team includes scientists with PhDs and medical degrees, though the firm has not disclosed a formal CEO or founding year. The company’s strategy rests on a diverse pipeline: its lead candidate CTX-187 targets Gram-negative bacterial infections and received FDA Qualified Infectious Disease Product (QIDP) designation in March 2026 (per firm press release, March 2026). A second compound, ABX-01, is progressing toward first-in-human trials with additional funding of $5.1M from CARB-X, awarded in July 2025. Centauri also operates an oncology arm, though details on specific programs are limited. Geographically, the firm is UK-based, with headquarters at Alderley Park, Cheshire, and a registered London address. As of February 2026, Centauri had extended its Series A to £30M, including a £6M investment from the AMR Action Fund — a dedicated antimicrobial resistance investor (per firm press release, February 2026). The company employs at least 17 professionals, as listed on its team page. It maintains no disclosed philanthropic or operating-company vehicles. Centauri’s differentiating structural feature is its Alphamer® platform, which redirects rather than engineering antibodies — a mechanism that may offer advantages in speed and breadth against resistant pathogens. The firm relies on grants and targeted venture funding, with CARB-X and the AMR Action Fund as notable non-dilutive and strategic backers.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
United Kingdom
City
London
Corporate office
Alderley Park, Nether Alderley, Cheshire SK10 4TG, United Kingdom
Principals
Jennifer Schneider
Team Member (PhD, MPH)
Helen Bright
Team Member (PhD, FRSM)
Debra Barker
Team Member (MD, MSc)
Samantha Macro
Team Member (PhD, MCA, MBA)
Hassan Al-Bewani
Team Member (PhD)
Antonia Atkinson
Team Member
Jessica Boyle
Team Member (PhD, MBA)
Matthew Bushdyhan
Team Member (MRes)
David Chapman
Team Member (PhD)
Zenobia D’Costa
Team Member (PhD)
Iman Hassanally
Strategy and Corporate Development Manager
Daniel Hynes
Team Member (BSc)
Adam Johnson
Team Member (PhD)
Lydia Jones
Team Member (PhD)
Khushi Khare
Team Member
Jaya Saini
Team Member (PhD)
Sector focus
Frequently asked questions
Who runs investment decisions at Centauri Therapeutics?
The company's team page lists senior scientists and a strategy manager, but Centauri has not publicly named a CEO, CIO, or managing principal. Investment decisions appear to rest with the listed leadership, including PhD-level researchers and the Strategy and Corporate Development Manager Iman Hassanally (per firm website).
How does Centauri Therapeutics source its funding?
The firm raises capital through venture rounds and non-dilutive grants. In February 2026, it extended its Series A to £30M with a £6M investment from the AMR Action Fund. It also receives grant funding from CARB-X, including a $5.1M award in July 2025 (per firm press releases).
What is Centauri's Alphamer® technology, and how is it different?
Alphamer® is a proprietary platform that redirects naturally existing antibodies in the body to target specific pathogens or cancer cells. Unlike traditional antibody engineering that creates new antibodies, Alphamer® leverages the patient's own immune system, potentially enabling faster and broader therapeutic application (per firm website).
Which sectors does Centauri explicitly avoid?
Centauri's public focus is limited to infectious diseases and oncology. The firm has not disclosed any sectors it explicitly avoids, but based on its pipeline and press releases, it does not appear active in areas such as gene therapy, rare diseases, or medical devices.
Is Centauri Therapeutics structured as a family office or asset manager?
No. Centauri appears to be an operating biotechnology company, not a family office or asset manager. It develops its own drug candidates and raises structured venture financing, similar to other early-stage biotech firms.
What regulatory milestones has Centauri achieved?
Centauri's lead candidate CTX-187 received FDA Qualified Infectious Disease Product (QIDP) designation in March 2026, which provides expedited development and regulatory pathways (per firm press release, March 2026).
What is the relationship between Centauri Therapeutics and the AMR Action Fund?
The AMR Action Fund invested £6M in Centauri's Series A extension closed in February 2026, making it a strategic investor. The Fund focuses on combating antimicrobial resistance and likely provides both capital and industry expertise (per firm press release, February 2026).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: